Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obalon Therapeutics Inc    OBLN

OBALON THERAPEUTICS INC (OBLN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Glancy Prongay & Murray LLP : Files Securities Class Action Lawsuit Against Obalon Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/15/2018 | 12:40am CEST

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of a class (the “Class”) consisting of persons and entities that acquired Obalon Therapeutics, Inc., (“Obalon” or the “Company”) (NASDAQ: OBLN) securities between October 5, 2016 and January 23, 2018, inclusive (the “Class Period”).

If you are a member of the Class described above, you may move the Court no later than 60 days from the date of this notice, to serve as lead plaintiff. Please contact Lesley Portnoy at 888-773-9224 or 310-201-9150, or at [email protected] to discuss this matter.

On January 23, 2018, Obalon issued a press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.” The Company further stated that “Obalon’s Audit Committee will oversee an internal investigation of these allegations.”

On this news, Obalon’s stock price fell $1.73 per share, or 33.3%, to close at $3.46 per share on January 23, 2018, on unusually heavy volume. The $3.46 closing price represented a total decline of $11.54, or nearly 77%, from the IPO price of $15.00 per share.

The filed complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles (“GAAP”); (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Obalon’s business, operations, and prospects, were materially false and misleading at all relevant times.

If you purchased shares of Obalon during the Class Period you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to [email protected], or visit our website at www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OBALON THERAPEUTICS INC
05/17Obalon Announces Upcoming Conference Presentation
GL
05/10OBALON THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
05/10OBALON THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
AQ
05/10Obalon Announces First Quarter 2018 Financial Results
GL
05/08OBALON THERAPEUTICS : Todd Wood joins Obalon Therapeutics, Inc. as Vice Presiden..
AQ
05/07Todd Wood joins Obalon Therapeutics, Inc. as Vice President Global Sales
GL
05/07OBALON THERAPEUTICS, INC. (NASDAQ : OBLN) Files An 8-K Departure of Directors or..
AQ
05/04OBALON THERAPEUTICS INC : Change in Directors or Principal Officers, Financial S..
AQ
05/04OBALON SCHEDULES FIRST QUARTER 2018 : 00 p.m. Eastern Time
GL
04/16OBALON THERAPEUTICS INC : DEADLINE TODAY: The Schall Law Firm Announces the Fili..
AC
More news
News from SeekingAlpha
05/12Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings C.. 
05/11Midday Gainers / Losers (05/11/2018) 
05/11Obalon down 32% on soft Q1 sales 
05/11HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/11/2018) 
05/10Obalon Therapeutics misses by $0.21, misses on revenue 
Financials ($)
Sales 2018 13,6 M
EBIT 2018 -37,7 M
Net income 2018 -38,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 3,39x
Capi. / Sales 2019 2,13x
Capitalization 46,1 M
Chart OBALON THERAPEUTICS INC
Duration : Period :
Obalon Therapeutics Inc Technical Analysis Chart | OBLN | US67424L1008 | 4-Traders
Technical analysis trends OBALON THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,25 $
Spread / Average Target 62%
EPS Revisions
Managers
NameTitle
Andrew P. Rasdal President, Chief Executive Officer & Director
Kim P. Kamdar Chairman
Kelly Huang Chief Operating Officer
William John Plovanic Chief Financial Officer & Secretary
Mark Brister Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
OBALON THERAPEUTICS INC-60.06%46
STRYKER CORPORATION11.61%64 581
SMITH & NEPHEW3.34%15 585
WRIGHT MEDICAL GROUP NV11.71%2 628
JAPAN LIFELINE CO., LTD.13.57%2 189
GLAUKOS CORP34.50%1 202